Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CWS-2007-HR maintenance therapy in high-risk rhabdomyosarcoma
2007-001478-10Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trofosfamide, etoposide and idarubicin in rhabdomyosarcoma (RMS) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: 3-year event-free survival. Started Jul 2008; status: completed.
02
Drugs
trofosfamideetoposideidarubicin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2007-001478-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001478-10.